Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Opdivo® (nivolumab) – Expanded indication
December 20, 2017 – Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
